Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey

DR Lim, AS Dean, MR Taguinod-Santiago, A Borbe-Reyes, AM Cabibbe, M Zignol, RP Basilio, AMC Garfin, MCG Ama

Research output: Contribution to journalArticle

Abstract

Antimicrobial resistance (AMR) represents a global threat to public health and security. Misuse of antibiotics is the leading cause of AMR worldwide. Infections that are typically easily treatable can become life-threatening or even deadly. Multidrug-resistant (MDR) tuberculosis (TB) (defined as resistance to at least rifampicin and isoniazid, the two most powerful first-line anti-TB drugs) and extensively drug-resistant (XDR)-TB (defined as MDR-TB with additional resistance to any fluoroquinolone and a second-line injectable (SLI) agent) are forms of TB that are complex to treat, require longer and more toxic regimens [1], and have considerably worse prognosis and outcome [2, 3]. Resistance to anti-TB drugs poses a major challenge to ending the global TB epidemic by 2030 [4]. To estimate the burden of drug-resistant TB, and plan diagnostic and treatment services, surveillance of drug resistance among TB patients has been conducted worldwide since the 1990s [5].
Original languageEnglish
Article number1702571
JournalEuropean Respiratory Journal
Volume51
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Philippines
Fluoroquinolones
Tuberculosis
Multidrug-Resistant Tuberculosis
Extensively Drug-Resistant Tuberculosis
Diagnostic Services
Poisons
Isoniazid
Rifampin
Drug Resistance
Pharmaceutical Preparations
Public Health
Surveys and Questionnaires
Anti-Bacterial Agents
Injections
Infection

Cite this

Lim, DR., Dean, AS., Taguinod-Santiago, MR., Borbe-Reyes, A., Cabibbe, AM., Zignol, M., ... Ama, MCG. (2018). Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. European Respiratory Journal, 51(3), [1702571]. https://doi.org/10.1183/13993003.02571-2017

Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. / Lim, DR; Dean, AS; Taguinod-Santiago, MR; Borbe-Reyes, A; Cabibbe, AM; Zignol, M; Basilio, RP; Garfin, AMC; Ama, MCG.

In: European Respiratory Journal, Vol. 51, No. 3, 1702571, 2018.

Research output: Contribution to journalArticle

Lim, DR, Dean, AS, Taguinod-Santiago, MR, Borbe-Reyes, A, Cabibbe, AM, Zignol, M, Basilio, RP, Garfin, AMC & Ama, MCG 2018, 'Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey', European Respiratory Journal, vol. 51, no. 3, 1702571. https://doi.org/10.1183/13993003.02571-2017
Lim, DR ; Dean, AS ; Taguinod-Santiago, MR ; Borbe-Reyes, A ; Cabibbe, AM ; Zignol, M ; Basilio, RP ; Garfin, AMC ; Ama, MCG. / Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey. In: European Respiratory Journal. 2018 ; Vol. 51, No. 3.
@article{d8fecf15de664266bd003a1b5ac34055,
title = "Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey",
abstract = "Antimicrobial resistance (AMR) represents a global threat to public health and security. Misuse of antibiotics is the leading cause of AMR worldwide. Infections that are typically easily treatable can become life-threatening or even deadly. Multidrug-resistant (MDR) tuberculosis (TB) (defined as resistance to at least rifampicin and isoniazid, the two most powerful first-line anti-TB drugs) and extensively drug-resistant (XDR)-TB (defined as MDR-TB with additional resistance to any fluoroquinolone and a second-line injectable (SLI) agent) are forms of TB that are complex to treat, require longer and more toxic regimens [1], and have considerably worse prognosis and outcome [2, 3]. Resistance to anti-TB drugs poses a major challenge to ending the global TB epidemic by 2030 [4]. To estimate the burden of drug-resistant TB, and plan diagnostic and treatment services, surveillance of drug resistance among TB patients has been conducted worldwide since the 1990s [5].",
author = "DR Lim and AS Dean and MR Taguinod-Santiago and A Borbe-Reyes and AM Cabibbe and M Zignol and RP Basilio and AMC Garfin and MCG Ama",
year = "2018",
doi = "10.1183/13993003.02571-2017",
language = "English",
volume = "51",
journal = "European Respiratory Journal",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Low prevalence of fluoroquinolone resistance among patients with tuberculosis in the Philippines: results of a national survey

AU - Lim, DR

AU - Dean, AS

AU - Taguinod-Santiago, MR

AU - Borbe-Reyes, A

AU - Cabibbe, AM

AU - Zignol, M

AU - Basilio, RP

AU - Garfin, AMC

AU - Ama, MCG

PY - 2018

Y1 - 2018

N2 - Antimicrobial resistance (AMR) represents a global threat to public health and security. Misuse of antibiotics is the leading cause of AMR worldwide. Infections that are typically easily treatable can become life-threatening or even deadly. Multidrug-resistant (MDR) tuberculosis (TB) (defined as resistance to at least rifampicin and isoniazid, the two most powerful first-line anti-TB drugs) and extensively drug-resistant (XDR)-TB (defined as MDR-TB with additional resistance to any fluoroquinolone and a second-line injectable (SLI) agent) are forms of TB that are complex to treat, require longer and more toxic regimens [1], and have considerably worse prognosis and outcome [2, 3]. Resistance to anti-TB drugs poses a major challenge to ending the global TB epidemic by 2030 [4]. To estimate the burden of drug-resistant TB, and plan diagnostic and treatment services, surveillance of drug resistance among TB patients has been conducted worldwide since the 1990s [5].

AB - Antimicrobial resistance (AMR) represents a global threat to public health and security. Misuse of antibiotics is the leading cause of AMR worldwide. Infections that are typically easily treatable can become life-threatening or even deadly. Multidrug-resistant (MDR) tuberculosis (TB) (defined as resistance to at least rifampicin and isoniazid, the two most powerful first-line anti-TB drugs) and extensively drug-resistant (XDR)-TB (defined as MDR-TB with additional resistance to any fluoroquinolone and a second-line injectable (SLI) agent) are forms of TB that are complex to treat, require longer and more toxic regimens [1], and have considerably worse prognosis and outcome [2, 3]. Resistance to anti-TB drugs poses a major challenge to ending the global TB epidemic by 2030 [4]. To estimate the burden of drug-resistant TB, and plan diagnostic and treatment services, surveillance of drug resistance among TB patients has been conducted worldwide since the 1990s [5].

U2 - 10.1183/13993003.02571-2017

DO - 10.1183/13993003.02571-2017

M3 - Article

VL - 51

JO - European Respiratory Journal

JF - European Respiratory Journal

SN - 0903-1936

IS - 3

M1 - 1702571

ER -